HomeCompareAE vs ABBV

AE vs ABBV: Dividend Comparison 2026

AE yields 2.53% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.8K in total portfolio value
10 years
AE
AE
● Live price
2.53%
Share price
$37.98
Annual div
$0.96
5Y div CAGR
12.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.6K
Annual income
$1,142.72
Full AE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AE vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AE
Annual income on $10K today (after 15% tax)
$214.85/yr
After 10yr DRIP, annual income (after tax)
$971.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,084.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AE + ABBV for your $10,000?

AE: 50%ABBV: 50%
100% ABBV50/50100% AE
Portfolio after 10yr
$65.0K
Annual income
$12,957.24/yr
Blended yield
19.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AE
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
8.8
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AE buys
0
ABBV buys
0
No recent congressional trades found for AE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAEABBV
Forward yield2.53%3.06%
Annual dividend / share$0.96$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12.9%40.6%
Portfolio after 10y$27.6K$102.3K
Annual income after 10y$1,142.72$24,771.77
Total dividends collected$6.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: AE vs ABBV ($10,000, DRIP)

YearAE PortfolioAE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,985$285.37$11,550$430.00$565.00ABBV
2$12,085$330.78$13,472$627.96$1.4KABBV
3$13,315$383.96$15,906$926.08$2.6KABBV
4$14,693$446.36$19,071$1,382.55$4.4KABBV
5$16,242$519.73$23,302$2,095.81$7.1KABBV
6$17,985$606.17$29,150$3,237.93$11.2KABBV
7$19,952$708.23$37,536$5,121.41$17.6KABBV
8$22,178$829.02$50,079$8,338.38$27.9KABBV
9$24,702$972.31$69,753$14,065.80$45.1KABBV
10$27,574$1,142.72$102,337$24,771.77$74.8KABBV

AE vs ABBV: Complete Analysis 2026

AEStock

Adams Resources & Energy, Inc., through its subsidiaries, primarily engages in the marketing, transportation, terminalling, and storage in various crude oil and natural gas basins in the United States. The company operates through three segments: Crude Oil Marketing, Transportation and Storage; Tank truck Transportation of Liquid Chemicals, Pressurized Gases, Asphalt and Dry Bulk; and Pipeline Transportation, Terminalling and Storage of Crude Oil. It purchases crude oil and arranges sales and deliveries to refiners and other customers primarily onshore in Texas, Oklahoma, North Dakota, Michigan, Wyoming, and Louisiana; and owns and operates a fleet of 201 tractor-trailer rigs and maintains approximately 180 pipeline inventory locations or injection stations. The company also transports liquid chemicals, pressurized gases, asphalt, and dry bulk on a for hire basis in the continental United States, and into Canada and Mexico; and operates nineteen truck terminals in Houston, Corpus Christi, Nederland, Freeport, Baton Rouge, St. Rose, Boutte, Sterlington, Jacksonville, Tampa, Atlanta, Augusta, Alabama, North Carolina, Ohio, West Virginia, Arkansas, East St. Louis, Joliet, Louisiana, and the Corpus Christi. In addition, it operates crude oil and condensate pipeline system, which connects the Eagle Ford Basin to the Gulf Coast waterborne market that has a capacity of 450,000 barrels per day. Adams Resources & Energy, Inc. was founded in 1947 and is headquartered in Houston, Texas.

Full AE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AE vs SCHDAE vs JEPIAE vs OAE vs KOAE vs MAINAE vs JNJAE vs MRKAE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.